Tianjin Lisheng Pharmaceutical Co.,Ltd.
002393.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.95B
Close$
$40.99
211.2% upside
Current Fair Value
211.2% upsideUndervalued by 211.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.95 Billion |
|---|---|
| Enterprise Value | $2.83 Billion |
| Dividend Yield | $0.85 (6.45%) |
| Earnings per Share | $1.62 |
| Beta | -0.09 |
| Outstanding Shares | 300,217,443 |
Return
| Return on Equity | 3.38% |
|---|---|
| Return on Assets | 2.84% |
| Return on Invested Capital | 2.95% |
Valuation & Multiples
| P/E Ratio | 22.78 |
|---|---|
| PEG | -25.09 |
| Price to Sales | 3.29 |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | 2.17 |
| Enterprise Value to EBIT | 20.51 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tianjin Lisheng Pharmaceutical Co.,Ltd.
1,605 employees
CEO: Fujun Wang Tianjin Lisheng Pharmaceutical Co.,Ltd. specializes in the manufacturing and distribution of chemical pharmaceutical products. Their extensive catalog features a variety of finished dosage forms, including tablets, hard capsules, drippin...